v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
OPERATING ACTIVITIES    
Net loss $ (24,574) $ (39,759)
Adjustments to reconcile net loss to net cash used in operating activities:    
Change in fair value of derivative liability (340) 26,320
Change in fair value of convertible preferred stock warrant liability (13) 1,365
Change in fair value of SARs liability (2) 39
Stock-based compensation 9,804 2,895
SARs issued to a customer recorded as a reduction to revenue 183 63
Inventory adjustments 4,361 1,761
Depreciation and amortization 1,657 907
Amortization of debt discounts and deferred financing costs 148 451
Non-cash interest 29 221
Changes in operating assets and liabilities:    
Accounts receivable (9,113) (12,120)
Inventory (2,971) (19,588)
Prepaid expenses and other assets (2,615) (439)
Accounts payable (2,001) 4,841
Accrued expenses and other liabilities 20,847 9,807
Net cash used in operating activities (4,600) (23,236)
INVESTING ACTIVITIES    
Purchase of property and equipment (3,438) (3,539)
Net cash used in investing activities (3,438) (3,539)
FINANCING ACTIVITIES    
Proceeds from issuance of common stock 155,366 0
Proceeds from term loan facility 0 14,000
Proceeds from line of credit 0 7,000
Proceeds from exercise of stock options 861 1,405
Payment of debt issuance costs 0 (463)
Repayment of line of credit (43,000) 0
Payment of offering costs (9,641) 0
Payment of deferred offering costs 0 (5,061)
Net cash provided by financing activities 103,586 16,881
Net change in cash and cash equivalents 95,548 (9,894)
Cash and cash equivalents, beginning of period 10,860 17,306
Cash and cash equivalents, end of period 106,408 7,412
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid for interest 342 1,311
Cash paid for income taxes 0 3
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Reallocation of borrowings from term loan to line of credit 0 22,000
Capital expenditures included in accounts payable and accrued expenses 173 473
Deferred offering costs included in accounts payable and accrued expenses 0 3,831
Deferred offering costs transferred to additional paid in capital 13,987 0
Conversion of convertible preferred stock to common stock 101,967 0
Conversion of convertible notes to equity 18,678 0
Reclassification of Derivative Liability to Equity 32,073 0
Reclassification of convertible warrant liability to equity $ 1,871 $ 0

Source